Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not seen ...

DelveInsight’s, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers ...

Learn more about whether Moderna, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, AlbionVC, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management ...

The company’s strong liquidity position is reflected in its current ratio of 5.58 ... Beam Therapeutics. This delay could present challenges in capturing market share and establishing Prime ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP ... could generate $1 billion in sales by 2026 and reach $3.5 billion by 2030, with early patient uptake already underway.

Liu co-founded Pairwise Plants, which applies base editing to agricultural crop improvements, and Beam Therapeutics ... and lungs. 5 In April 2024, the FDA approved the first clinical trial of a prime ...

Black Diamond Therapeutics, Inc. shows promising developments ... It's not ready for prime time just yet. BDTX anticipates getting FDA feedback on a potential path to approval in Q1 2025.

Hyyve Inc., Canada's first real estate agent listing-bid platform and performance-driven marketplace, is proud to announce the appointment of renowned luxury real estate expert Peter Torkan to its ...

Cathie Wood, ARK Invest buy two stocks on Wednesday, Thursday as Trump tariffs rake the market. Wood previously warned of a ...